{"id":3661,"date":"2020-10-01T12:07:07","date_gmt":"2020-10-01T11:07:07","guid":{"rendered":"https:\/\/www.ab-science.com\/covid-19\/"},"modified":"2021-10-06T11:05:51","modified_gmt":"2021-10-06T10:05:51","slug":"covid-19","status":"publish","type":"page","link":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/covid-19\/","title":{"rendered":"COVID-19"},"content":{"rendered":"

[vc_row css=\u00a0\u00bb.vc_custom_1633514202311{background-color: #00477a !important;border: 10px solid #00477a !important;border-radius: 10px !important;}\u00a0\u00bb][vc_column css=\u00a0\u00bb.vc_custom_1633514590586{padding-top: 20px !important;}\u00a0\u00bb][vc_column_text css=\u00a0\u00bb.vc_custom_1633514499321{margin-bottom: 20px !important;}\u00a0\u00bb]<\/p>\n

Si vous souhaitez participer \u00e0 l\u2019\u00e9tude en cours, veuillez nous contacter \u00e0 clinical@ab-science.com<\/a>\u200b<\/p>\n

[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column]

<\/span>\u00c0 propos de la COVID-19<\/span><\/div><\/div>
<\/div>[vc_column_text]La COVID-19 est une maladie respiratoire d\u00e9clench\u00e9e par un nouveau coronavirus (SARS-CoV-2) qui entra\u00eene une morbidit\u00e9 et une mortalit\u00e9 importantes. Depuis l’apparition du SRAS-CoV-2 en Chine en d\u00e9cembre 2019, la pand\u00e9mie s’est propag\u00e9e de mani\u00e8re continue et rapide dans le monde entier. \u00c0 ce jour, aucun traitement n’a d\u00e9montr\u00e9 un effet positif sur les patients COVID-19 hospitalis\u00e9s.<\/p>\n

Il y a donc un besoin urgent en sant\u00e9 publique pour le d\u00e9veloppement rapide de nouvelles possibilit\u00e9s th\u00e9rapeutiques.[\/vc_column_text]

<\/span>Positionnement du masitinib sur la COVID-19<\/span><\/div><\/div>
<\/div>
<\/span>Positionnement du masitinib dans les formes mod\u00e9r\u00e9es et s\u00e9v\u00e8res de COVID-19<\/span><\/div><\/div>
<\/div>[vc_column_text]De nombreux patients atteints de COVID-19 mod\u00e9r\u00e9s et graves d\u00e9veloppent une \u00ab\u00a0temp\u00eate de cytokines\u00a0\u00bb qui entra\u00eene une inflammation pulmonaire grave et divers \u00e9v\u00e9nements thrombotiques associ\u00e9s \u00e0 un syndrome de d\u00e9tresse respiratoire aigu\u00eb (SDRA) et potentiellement la mort.<\/p>\n

Il est prouv\u00e9 que les mastocytes pourraient contribuer \u00e0 l’inflammation induite par la COVID-19 en activant la lib\u00e9ration pr\u00e9coce de compos\u00e9s inflammatoires et que les macrophages pourraient contribuer \u00e0 une inflammation excessive et \u00e0 la mort des cellules lymphocytaires induite par l’activation durant l’infection par la COVID-191<\/sup>.<\/p>\n

Par cons\u00e9quent, le syndrome de la \u00ab\u00a0temp\u00eate de cytokines\u00a0\u00bb et les l\u00e9sions pulmonaires pourraient \u00eatre \u00e9vit\u00e9s par l’inhibition des mastocytes et par l’activit\u00e9 des macrophages.<\/p>\n

\u00c9tant donn\u00e9 que le masitinib inhibe l’activit\u00e9 des mastocytes et des macrophages, il existe une forte justification pour d\u00e9velopper le masitinib dans le traitement des formes mod\u00e9r\u00e9es et graves de COVID-19.[\/vc_column_text]

<\/span>Le masitinib se positionne comme un traitement antiviral pour la COVID-19<\/span><\/div><\/div>
<\/div>[vc_column_text]Une \u00e9tude ind\u00e9pendante men\u00e9e par l’Universit\u00e9 de Chicago a r\u00e9cemment rapport\u00e9 que le masitinib in vitro<\/em> produit un fort effet anti-viral sur le virus du SRAS-CoV-22<\/sup>.<\/p>\n

\u00c0 partir d’une biblioth\u00e8que initiale de 1 900 compos\u00e9s, soit approuv\u00e9s pour l’utilisation chez l’homme, ayant fait l’objet de nombreuses donn\u00e9es de s\u00e9curit\u00e9 chez l’humain, le masitinib a \u00e9t\u00e9 identifi\u00e9 comme le compos\u00e9 antiviral le plus puissant, puisqu’il a totalement abrog\u00e9 la production du SRAS-CoV-2.<\/p>\n

En particulier, le masitinib se distingue par sa capacit\u00e9 \u00e0 inhiber compl\u00e8tement l’activit\u00e9 de la principale prot\u00e9ase du SRAS-CoV-2 (3CLpro), bloquant ainsi la r\u00e9plication virale.<\/p>\n

En Janvier 2021, une \u00e9tude ind\u00e9pendante de l’Institut de virologie humaine (Guangzhou, Chine) a confirm\u00e9 l\u2019activit\u00e9 anti-virale du masitinib in vitro<\/em> contre le virus SARS-CoV-23<\/sup>.[\/vc_column_text]

<\/span>\u00c9tude de Phase 2 en cours avec le masitinib dans les cas mod\u00e9r\u00e9s et graves de COVID-19<\/span><\/div><\/div>
<\/div>[vc_column_text]AB Science a re\u00e7u l’autorisation de l’Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament (ANSM) de lancer une \u00e9tude de Phase 2 \u00e9valuant le masitinib en association avec l’isoquerc\u00e9tine pour le traitement de la COVID-19 mod\u00e9r\u00e9 et s\u00e9v\u00e8re. L’\u00e9tude permettra de recruter des patients en France et dans d’autres pays. Le premier objectif est d’am\u00e9liorer l’\u00e9tat clinique des patients apr\u00e8s 15 jours de traitement.[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]R\u00e9f\u00e9rences<\/em><\/strong><\/p>\n
    \n
  1. Kritas, S. K. et al. Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. J. Biol. Regul. Homeost. Agents 34, (2020).<\/em><\/li>\n
  2. Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro by Drayman N et al. in bioRxiv (2020).<\/em><\/li>\n
  3. Luo Y, Yu F, Zhou M, et al. 2021. Engineering a reliable and convenient SARS-CoV-2 replicon system for analysis of viral RNA synthesis and screening of antiviral inhibitors. mBio 12:e02754-20. https:\/\/doi.org\/10.1128\/mBio.02754<\/a><\/em><\/li>\n<\/ol>\n

    [\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"

    [vc_row css=\u00a0\u00bb.vc_custom_1633514202311{background-color: #00477a !important;border: 10px solid #00477a !important;border-radius: 10px !important;}\u00a0\u00bb][vc_column css=\u00a0\u00bb.vc_custom_1633514590586{padding-top: 20px !important;}\u00a0\u00bb][vc_column_text css=\u00a0\u00bb.vc_custom_1633514499321{margin-bottom: 20px !important;}\u00a0\u00bb] Si vous souhaitez participer \u00e0 l\u2019\u00e9tude en cours, veuillez nous contacter \u00e0 clinical@ab-science.com\u200b [\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]La COVID-19 est une maladie respiratoire d\u00e9clench\u00e9e par un nouveau coronavirus (SARS-CoV-2) qui entra\u00eene une morbidit\u00e9 et une mortalit\u00e9 importantes. Depuis l’apparition du SRAS-CoV-2 en Chine…<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":3763,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-3661","page","type-page","status-publish","hentry","description-off"],"yoast_head":"\nPositionnement du masitinib sur la COVID-19<\/title>\n<meta name=\"description\" content=\"Il existe une forte justification pour d\u00e9velopper le masitinib dans le traitement des formes mod\u00e9r\u00e9es et graves de COVID-19\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/covid-19\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"COVID-19\" \/>\n<meta property=\"og:description\" content=\"Il existe une forte justification pour d\u00e9velopper le masitinib dans le traitement des formes mod\u00e9r\u00e9es et graves de COVID-19\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/covid-19\/\" \/>\n<meta property=\"og:site_name\" content=\"AB Science\" \/>\n<meta property=\"article:modified_time\" content=\"2021-10-06T10:05:51+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/covid-19\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/covid-19\\\/\",\"name\":\"Positionnement du masitinib sur la COVID-19\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\"},\"datePublished\":\"2020-10-01T11:07:07+00:00\",\"dateModified\":\"2021-10-06T10:05:51+00:00\",\"description\":\"Il existe une forte justification pour d\u00e9velopper le masitinib dans le traitement des formes mod\u00e9r\u00e9es et graves de COVID-19\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/covid-19\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/covid-19\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-apercu\\\/covid-19\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pipeline\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Masitinib\",\"item\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/pipeline\\\/masitinib-overview\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"COVID-19\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"name\":\"AB Science\",\"description\":\"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#organization\",\"name\":\"AB Science\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"contentUrl\":\"https:\\\/\\\/www.ab-science.com\\\/wp-content\\\/uploads\\\/2020\\\/11\\\/logo_ab-science-wh120.png\",\"width\":120,\"height\":120,\"caption\":\"AB Science\"},\"image\":{\"@id\":\"https:\\\/\\\/www.ab-science.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ab-science\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Positionnement du masitinib sur la COVID-19","description":"Il existe une forte justification pour d\u00e9velopper le masitinib dans le traitement des formes mod\u00e9r\u00e9es et graves de COVID-19","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/covid-19\/","og_locale":"fr_FR","og_type":"article","og_title":"COVID-19","og_description":"Il existe une forte justification pour d\u00e9velopper le masitinib dans le traitement des formes mod\u00e9r\u00e9es et graves de COVID-19","og_url":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/covid-19\/","og_site_name":"AB Science","article_modified_time":"2021-10-06T10:05:51+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/covid-19\/","url":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/covid-19\/","name":"Positionnement du masitinib sur la COVID-19","isPartOf":{"@id":"https:\/\/www.ab-science.com\/fr\/#website"},"datePublished":"2020-10-01T11:07:07+00:00","dateModified":"2021-10-06T10:05:51+00:00","description":"Il existe une forte justification pour d\u00e9velopper le masitinib dans le traitement des formes mod\u00e9r\u00e9es et graves de COVID-19","breadcrumb":{"@id":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/covid-19\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/covid-19\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-apercu\/covid-19\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.ab-science.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Pipeline","item":"https:\/\/www.ab-science.com\/fr\/pipeline\/"},{"@type":"ListItem","position":3,"name":"Masitinib","item":"https:\/\/www.ab-science.com\/fr\/pipeline\/masitinib-overview\/"},{"@type":"ListItem","position":4,"name":"COVID-19"}]},{"@type":"WebSite","@id":"https:\/\/www.ab-science.com\/fr\/#website","url":"https:\/\/www.ab-science.com\/fr\/","name":"AB Science","description":"Masitinib and AB8939 \u2013 Two compounds with breakthrough mechanism of action","publisher":{"@id":"https:\/\/www.ab-science.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ab-science.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ab-science.com\/fr\/#organization","name":"AB Science","url":"https:\/\/www.ab-science.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","contentUrl":"https:\/\/www.ab-science.com\/wp-content\/uploads\/2020\/11\/logo_ab-science-wh120.png","width":120,"height":120,"caption":"AB Science"},"image":{"@id":"https:\/\/www.ab-science.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/ab-science\/"]}]}},"_links":{"self":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages\/3661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/comments?post=3661"}],"version-history":[{"count":0,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages\/3661\/revisions"}],"up":[{"embeddable":true,"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/pages\/3763"}],"wp:attachment":[{"href":"https:\/\/www.ab-science.com\/fr\/wp-json\/wp\/v2\/media?parent=3661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}